EL7.AI
StocksMedium•31 July 2026•
1 min read

Moderna Reports $0.8B Q2 Loss While Improving 2026 Expense Outlook

Key Facts

1Moderna reported Q2 2026 revenue of $0.1 billion and a net loss of $0.8 billion.
2Moderna improved its 2026 operating expense outlook by $0.2 billion and awaits an August 5 PDUFA date for its influenza vaccine.
3AutoNation reported Q2 revenue of $6.9 billion and adjusted EPS of $5.56.

Amid ongoing financial shifts in the post-pandemic biotech sector, Moderna reported its Q2 2026 financial results, highlighting a net loss of $0.8 billion. The company generated $0.1 billion in revenue for the quarter, reflecting a transitional phase in its product pipeline. However, management signaled a move toward tighter cost discipline by improving its 2026 operating expense outlook by approximately $0.2 billion compared to previous estimates.

In the broader corporate landscape, AutoNation demonstrated stable performance with Q2 revenue reaching $6.9 billion and an adjusted EPS of $5.56. Per market data, AutoNation (AN) shares closed at $214.65 on July 30, 2026. During the same session, Moderna (MRNA) shares closed at $57.92, as investors weighed the company's significant quarterly loss against its improved full-year cash and expense guidance.

Traders are monitoring MRNA price levels following its close at $57.92 (close July 30, 2026), with attention turning to upcoming regulatory catalysts. A key event to watch is the August 5 PDUFA date for Moderna's investigational influenza vaccine, which could serve as a major fundamental driver. Additionally, broader market sentiment remains tied to upcoming US economic data releases scheduled for early August.